Alana Harris Dent

Array ( [id] => 12127513 [patent_doc_number] => 20180011098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'METHODS AND KITS FOR ANALYSIS OF HMGB1 ISOFORMS' [patent_app_type] => utility [patent_app_number] => 15/544835 [patent_app_country] => US [patent_app_date] => 2016-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 35894 [patent_no_of_claims] => 101 [patent_no_of_ind_claims] => 48 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13447163 [patent_doc_number] => 20180275124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => Modulators of the function of the core domain of annexins, and uses thereof in autoimmune and/or cancer therapy [patent_app_type] => utility [patent_app_number] => 15/541709 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15541709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12387834 [patent_doc_number] => 09963517 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-08 [patent_title] => Isoform specific anti-HER4 antibodies [patent_app_type] => utility [patent_app_number] => 14/946318 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 41277 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14946318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969915 [patent_doc_number] => 20170274069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'METHOD FOR THE CANCER TREATMENT AND PREVENTION OF METASTATIC DISEASE' [patent_app_type] => utility [patent_app_number] => 15/521855 [patent_app_country] => US [patent_app_date] => 2015-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 8909 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15521855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943313 [patent_doc_number] => 20170247464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases' [patent_app_type] => utility [patent_app_number] => 15/518803 [patent_app_country] => US [patent_app_date] => 2015-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11464 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678061 [patent_doc_number] => 20160024206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma' [patent_app_type] => utility [patent_app_number] => 14/877450 [patent_app_country] => US [patent_app_date] => 2015-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5997 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14877450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16291325 [patent_doc_number] => 10768167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/514255 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 10642 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11994288 [patent_doc_number] => 20170298444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'METHODS FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER' [patent_app_type] => utility [patent_app_number] => 15/514152 [patent_app_country] => US [patent_app_date] => 2015-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 12192 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11994205 [patent_doc_number] => 20170298360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'LATS AND BREAST CANCER' [patent_app_type] => utility [patent_app_number] => 15/513935 [patent_app_country] => US [patent_app_date] => 2015-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 26296 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14171713 [patent_doc_number] => 10259852 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Conjugate comprising P21 protein for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 14/861923 [patent_app_country] => US [patent_app_date] => 2015-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 5460 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14861923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10730947 [patent_doc_number] => 20160077098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS' [patent_app_type] => utility [patent_app_number] => 14/853254 [patent_app_country] => US [patent_app_date] => 2015-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 2151 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14853254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943295 [patent_doc_number] => 20170247446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/508036 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 13793 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15508036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10735930 [patent_doc_number] => 20160082079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-24 [patent_title] => 'Wnt Antagonist and Methods of Treatment and Screening' [patent_app_type] => utility [patent_app_number] => 14/842398 [patent_app_country] => US [patent_app_date] => 2015-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 39264 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14842398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001887 [patent_doc_number] => 20170306042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS' [patent_app_type] => utility [patent_app_number] => 15/507316 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 11462 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15507316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023673 [patent_doc_number] => 20170313771 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'Antibody for Recognizing Specific Motif of WLS Protein, and Pharmaceutical Composition Comprising Same' [patent_app_type] => utility [patent_app_number] => 15/518077 [patent_app_country] => US [patent_app_date] => 2015-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 12780 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11018085 [patent_doc_number] => 20160215039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'AGENTS AND METHODS BASED ON THE USE OF THE EDA DOMAIN OF FIBRONECTIN' [patent_app_type] => utility [patent_app_number] => 14/835764 [patent_app_country] => US [patent_app_date] => 2015-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 13605 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14835764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13345833 [patent_doc_number] => 20180224456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => METHOD FOR DETERMINING A SUBJECT'S PROBABILITY TO SUFFER FROM PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 15/506425 [patent_app_country] => US [patent_app_date] => 2015-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15506425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11944426 [patent_doc_number] => 20170248578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'ANTI-CANCER AGENT SENSITIVITY-DETERMINING MARKER' [patent_app_type] => utility [patent_app_number] => 15/503878 [patent_app_country] => US [patent_app_date] => 2015-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10964 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11031617 [patent_doc_number] => 20160228573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-11 [patent_title] => 'LIPOSOME ENCAPSULATED AFFINITY DRUG' [patent_app_type] => utility [patent_app_number] => 14/826967 [patent_app_country] => US [patent_app_date] => 2015-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 19336 [patent_no_of_claims] => 142 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14826967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11867595 [patent_doc_number] => 20170234880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'DIAGNOSIS OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/503155 [patent_app_country] => US [patent_app_date] => 2015-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 18206 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503155 [rel_patent_id] =>[rel_patent_doc_number] =>)